Key Players
Competitive Landscape
Postbiotic supply is organized around ownership of named preparations, and three supplier models compete for brand contracts. Integrated biotics platforms will add share by bundling postbiotics with probiotics and formulation services, and ingredient specialists will sell named preparations with focused digestive or immune claims. Strain owners such as Kirin are reaching foreign buyers through licensing, shown by the May 2025 IMMUSE agreement with Lallemand. Ownership also changed in 2025 when Probi became part of Symrise, and Probi launched Rham271h as the company's first postbiotic in May 2026. Kerry studied Plenibiotic among GLP-1 users in February 2026, and stability data paired with human evidence will set contract terms through 2036.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Lallemand | May 2025: distribution agreement with Kirin for the IMMUSE postbiotic | Brands want immune products with clinical backing. | Strain owners are licensing postbiotics to global distributors. | Wider distribution can bring a Japanese strain into new supplement markets. |
| DSM-Firmenich | February 2026: Humiome Post LB in an allergen-free version for gummies | Shoppers want easy, pleasant supplement formats. | Postbiotics are moving into chews and gummies. | Allergen-free grades can open family and adult gummy lines. |
| Kerry | February 2026: Plenibiotic consumer perception study among US GLP-1 users | GLP-1 users report digestive discomfort. | Postbiotics are targeting specific user groups. | Need-specific claims can support premium pricing. |
| Lallemand | April 2026: IMMUSE featured at Vitafoods Barcelona in a broad biotics line-up | Buyers want one supplier across several health needs. | Postbiotics now sit beside probiotics in supplier portfolios. | Bundled offers can shorten brand qualification. |
| Probi | May 2026: Rham271h launched as the company's first postbiotic at Vitafoods Europe | Formulators want cultures that survive heat and storage. | Probiotic strain owners are adding inactivated versions. | Stable preparations can enter complex formulas and new formats. |
Source: Future Market Insights, Postbiotic Supplements Market Report, 2026-2036.
Who Leads the Postbiotic Supplements Market?
Leadership in postbiotic supplements is split across three supplier models, with no company holding control of supply. DSM-Firmenich and Novonesis lead in integrated biotics platforms with formulation support. Kerry Group plc, Lallemand Inc. and Probi AB lead in named postbiotic ingredients for digestive and immune positions. Kirin Holdings Company, Limited leads as a strain owner licensing a clinically studied preparation.
Which Companies Run Integrated Biotics Platforms?
DSM-Firmenich and Novonesis run the two integrated biotics platforms profiled, each pairing postbiotics with probiotics and formulation support. DSM-Firmenich reported in February 2026 that Humiome Post LB had launched in an allergen-free version for gummies, and Novonesis lists Pylopass in powder form within the gastrointestinal health range of the Human Health portfolio.
Which Companies Supply Named Postbiotic Ingredients?
Kerry Group plc, Lallemand Inc. and Probi AB supply named postbiotic ingredients, each attaching a preparation to one health position. Kerry published a Plenibiotic study among US GLP-1 users in February 2026. Lallemand agreed to distribute IMMUSE in May 2025, and Probi launched Rham271h at Vitafoods Europe in May 2026.
Which Companies License Postbiotic Strains?
Kirin Holdings Company, Limited is the profiled licensor, having developed the heat-inactivated Lactococcus lactis strain Plasma. A May 2025 agreement with Lallemand brings the preparation to supplement brands outside Japan as IMMUSE for immune support.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| DSM-Firmenich | Nutrition and biotics group with postbiotic, probiotic and consumer-format capabilities. | In February 2026, DSM-Firmenich reported that Humiome Post LB had launched in an allergen-free version designed for gummy applications. |
| Novonesis | Biosolutions group with a Human Health portfolio covering probiotics and postbiotics. | Novonesis lists Pylopass in powder form within the gastrointestinal health range of the Human Health portfolio. |
| Kerry Group plc | Taste and nutrition company with a postbiotic aimed at digestive comfort. | In February 2026, Kerry published a four-week US consumer perception study of Plenibiotic among GLP-1 users. |
| Lallemand Inc. | Biotics supplier using partnership access and clinically documented immune positioning. | In May 2025, Lallemand Health Solutions agreed with Kirin Holdings to distribute IMMUSE, and featured the postbiotic at Vitafoods Barcelona in 2026. |
| Probi AB | Swedish probiotic strain developer, part of Symrise since 2025, now adding postbiotics. | In May 2026, Probi launched Rham271h, a heat-inactivated Lacticaseibacillus rhamnosus 271 preparation, at Vitafoods Europe. |
| Kirin Holdings Company, Limited | Japanese beverage and health group that owns the heat-inactivated strain Plasma. | In May 2025, Kirin Holdings signed a distribution agreement with Lallemand Health Solutions for IMMUSE. |
Company Selection and Benchmark Notes
Companies enter the benchmark when cited evidence links a company's postbiotic preparations, formats or supply roles to this market. The profiled set spans integrated biotics platforms, postbiotic ingredient specialists and strain owners, with Kirin Holdings Company, Limited included as the owner of the IMMUSE strain. Deerland Probiotics & Enzymes is scored under the parent, Novonesis, so no business is scored twice. Probi AB is scored as a Symrise company following the 2025 change of ownership. The benchmark uses documented criteria and scores limited public documentation as Low. Stated applications connect each company development to demand drivers and product trends.